To excise or not: impact of MelaFind on German dermatologists’ decisions to biopsy atypical lesions
Axel Hauschild(Kiel University), Dina Gutkowicz–Krusin(STRATA Skin Sciences (United States)), Jeff Goldsmith(Columbia University), Daniel O. Scharfstein(Johns Hopkins University), Hadley C. King(Cornell University), Suephy C. Chen(Emory University), Andreas Blum(Klinikum Konstanz), Michael Weichenthal(University Hospital Schleswig-Holstein)
Cited by 46
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
A National Evaluation of the Effect of Trauma-Center Care on Mortality
|New England Journal of Medicine|2006|2.6k
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
|Nature Genetics|2009|1.4k